Brief: Xencor's IL2-FC Cytokine, XmAb564, Is Well-Tolerated, Selectively Expands Regulatory T Cells In Phase 1A Clinical Study
07/11/2022 21:39
Nov 7 (Reuters) - Xencor Inc XNCR.O :
* XENCOR’S IL2-FC CYTOKINE, XMAB®564, IS WELL-TOLERATED AND
SELECTIVELY EXPANDS REGULATORY T CELLS IN PHASE 1A CLINICAL
STUDY
Source text for Eikon: ID:nBw7KqhNJa
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates